Metabolic Reprogramming in the Bladder Cancer Microenvironment: Bridging Fundamental Research and Therapeutic Avenues for Cancer-Associated Fibroblasts.

Ana Silva, Fátima Baltazar, Julieta Afonso

Abstract readReview

In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ana SilvaLife and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal.

Fátima BaltazarLife and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal.

Julieta AfonsoLife and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is one of the most common malignancies of the urinary tract, characterized by high recurrence rates and, in advanced stages, resistance to therapy and poor prognosis. Cancer and stromal cells of the BC microenvironment often undergo metabolic reprogramming to meet the demands of rapid growth and survival. These metabolic changes enable cancer cells to thrive under stressful conditions, support drug resistance, and contribute to tumor progression. Bladder cancer-associated fibroblasts (BCAFs) are key components of the tumor microenvironment and play a significant role in BC development and progression. Besides influencing cancer cell metabolism by altering nutrient availability and facilitating metabolic crosstalk, they secrete growth factors, cytokines, and extracellular matrix proteins that support tumor growth, modulate immune responses, and promote invasion, metastasis and resistance to therapy. In this review, we compiled current knowledge on the origin, development, function, and potential therapeutic applications of BCFAs. Particular emphasis was placed on the metabolic interplay between BCAFs and BC cells, as well as their mutual modulation.

Indexed as

Cancer-Associated FibroblastsMetabolic ReprogrammingTumor MicroenvironmentUrinary Bladder NeoplasmsAnimalsHumansBladder cancer microenvironmentCancer-associated fibroblastsLactate Monocarboxylate transportersMetabolic reprogrammingTherapeutic targeting of stroma

Identifiers

PMID42435169

DOI10.1038/srep11924

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.